Oxidative Stress and Huntington's Disease: The Good, the Bad, and the Ugly

Journal of Huntington's Disease

Volumn 5, Issue 3, 2016, Pages 217-237

  Kumar, Amit ^a,b   Ratan, Rajiv R ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

Author keywords

Huntington's Disease; Oxidative stress; redox changes; transcriptional processes

Indexed keywords

POLYGLUTAMINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

DNA DAMAGE; DNA REPAIR; HUMAN; HUNTINGTON CHOREA; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; PHYSIOLOGY;

HUMANS; HUNTINGTON DISEASE; OXIDATIVE STRESS;

EID: 84990068641     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-160205     Document Type: Review

References (181)

1. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57(5):369-84. PubMed PMID: 9596408.
2. Ross CA, Tabrizi SJ. Huntington's disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83-98. PubMed PMID: 21163446.
3. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72(6):971-83. PubMed PMID: 8458085.
4. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR, International Huntington's Disease Collaborative G. Anewmodel for prediction of the age of onset and penetrance for Huntington's disease based onCAGlength. Clin Genet. 2004;65(4):267-77. PubMed PMID: 15025718.
5. Gipson TA, Neueder A, Wexler NS, Bates GP, Housman D. Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis. RNA Biol. 2013;10(11):1647-52. PubMed PMID: 24256709. Pubmed Central PMCID: 3907474.
6. HattersDM. Putting huntingtin "aggregation" in viewwith windows into the cellular milieu. Curr Top Med Chem. 2012;12(22):2611-22. PubMed PMID: 23339311.
7. Kumar A, Vaish M, Ratan RR. Transcriptional dysregulation in Huntington's disease: A failure of adaptive transcriptional homeostasis. Drug Discov Today. 2014;19(7):956-62. PubMed PMID: 24662036. Pubmed Central PMCID: 4082751.
8. Mochel F, Haller RG. Energy deficit in Huntington disease: Why it matters. J Clin Invest. 2011;121(2):493-9. PubMed PMID: 21285522. Pubmed Central PMCID: 3026743.
9. Yano H, Baranov SV, Baranova OV, Kim J, Pan Y, Yablonska S, et al. Inhibition of mitochondrial protein import by mutant huntingtin. Nat Neurosci. 2014;17(6):822-31. PubMed PMID: 24836077. Pubmed Central PMCID: 4174557.
10. Ayala-Pena S. Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis. Free Radic Biol Med. 2013;62:102-10. PubMed PMID: 23602907. Pubmed Central PMCID: 3722255.
11. Pitts A, Dailey K, Newington JT, Chien A, Arseneault R, Cann T, et al. Dithiol-based compounds maintain expression of antioxidant protein peroxiredoxin 1 that counteracts toxicity of mutant huntingtin. J Biol Chem. 2012;287(27):22717-29. PubMed PMID: 22577145. Pubmed Central PMCID: 3391089.
12. Rotblat B, Southwell AL, Ehrnhoefer DE, Skotte NH, Metzler M, Franciosi S, et al. HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. Proc Natl Acad Sci U S A. 2014;111(8):3032-7. PubMed PMID: 24516159. Pubmed Central PMCID: 3939919.
13. Reijonen S, Kukkonen JP, Hyrskyluoto A, Kivinen J, Kairisalo M, TakeiN, et al. Downregulation of NF-kappaB signaling by mutant huntingtin proteins induces oxidative stress and cell death. Cell Mol Life Sci. 2010;67(11):1929-41. PubMed PMID: 20232225.
14. Molero AE, Arteaga-Bracho EE, Chen CH, Gulinello M, Winchester ML, Pichamoorthy N, et al. Selective expression of mutant huntingtin during development recapitulates characteristic features of Huntington's disease. Proc Natl Acad Sci U S A. 2016;113(20):5736-41. PubMed PMID: 27140644. Pubmed Central PMCID: 4878495.
15. Sepers MD, Raymond LA. Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease. Drug Discov Today. 2014;19(7):990-6. PubMed PMID: 24603212.
16. Crotti A, Benner C, Kerman BE, Gosselin D, Lagier-Tourenne C, Zuccato C, et al. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineagedetermining factors. Nat Neurosci. 2014;17(4):513-21. PubMed PMID: 24584051. Pubmed Central PMCID: 4113004.
17. Andre R, Carty L, Tabrizi SJ. Disruption of immune cell function by mutant huntingtin in Huntington's disease pathogenesis. Curr Opin Pharmacol. 2016;26:33-8. PubMed PMID: 26461267.
18. Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003;35(1):76-83. PubMed PMID: 12881722.
19. Twelvetrees AE, Yuen EY, Arancibia-Carcamo IL, MacAskill AF, Rostaing P, Lumb MJ, et al. Delivery of GABAARs to synapses is mediated by HAP1-KIF5 and disrupted by mutant huntingtin. Neuron. 2010;65(1):53-65. PubMed PMID: 20152113. Pubmed Central PMCID: 2841506.
20. Ochaba J, Lukacsovich T, Csikos G, Zheng S, Margulis J, Salazar L, et al. Potential function for the Huntingtin protein as a scaffold for selective autophagy. Proc Natl Acad Sci U S A. 2014;111(47):16889-94. PubMed PMID: 25385587. Pubmed Central PMCID: 4250109.
21. Rui YN, Xu Z, Patel B, Chen Z, Chen D, Tito A, et al. Huntingtin functions as a scaffold for selective macroautophagy. Nat Cell Biol. 2015;17(3):262-75. PubMed PMID: 25686248. Pubmed Central PMCID: 4344873.
22. Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathol. 1999;9(1):147-63. PubMed PMID: 9989457.
23. Polidori MC, Mecocci P, Browne SE, Senin U, Beal MF. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci Lett. 1999;272(1):53-6. PubMed PMID: 10507541.
24. Stack EC, Matson WR, Ferrante RJ. Evidence of oxidant damage in Huntington's disease: Translational strategiesusing antioxidants. Ann N Y Acad Sci. 2008;1147:79-92. PubMed PMID: 19076433.
25. Sorolla MA, Reverter-Branchat G, Tamarit J, Ferrer I, Ros J, Cabiscol E. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic Biol Med. 2008;45(5):667-78. PubMed PMID: 18588971.
26. Perluigi M, Poon HF, Maragos W, Pierce WM, Klein JB, Calabrese V, et al. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: A model of Huntington disease. Mol Cell Proteomics. 2005;4(12):1849-61. PubMed PMID: 15968004.
27. Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, et al. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord. 1996;11(3):321-3. PubMed PMID: 8723151.
28. Huntington Study G. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001;57(3):397-404. PubMed PMID: 11502903.
29. Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology. 2006;66(2):250-2. PubMed PMID: 16434666.
30. Huntington Study Group T-HDI. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: The TREND-HD study. Arch Neurol. 2008;65(12):1582-9. PubMed PMID: 19064745.
31. Ranen NG, Peyser CE, Coyle JT, Bylsma FW, Sherr M, Day L, et al. A controlled trial of idebenone in Huntington's disease. Mov Disord. 1996;11(5):549-54. PubMed PMID: 8866496.
32. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group. Neurology. 1998;50(5):1366-73. PubMed PMID: 9595988.
33. Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet. 2000;9(9):1259-71. PubMed PMID: 10814708.
34. Achour M, Le Gras S, Keime C, Parmentier F, Lejeune FX, Boutillier AL, et al. Neuronal identity genes regulated by super-enhancers are preferentially down-regulated in the striatum of Huntington's disease mice. Hum Mol Genet. 2015;24(12):3481-96. PubMed PMID: 25784504.
35. Iannicola C, Moreno S, Oliverio S, Nardacci R, Ciofi-Luzzatto A, Piacentini M. Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease. J Neurochem. 2000;75(2):830-9. PubMed PMID: 10899961.
36. Pisoschi AM, Pop A. The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem. 2015;97:55-74. PubMed PMID: 25942353.
37. Weidinger A, Kozlov AV. Biological Activities of Reactive Oxygen and Nitrogen Species: Oxidative Stress versus Signal Transduction. Biomolecules. 2015;5(2):472-84. PubMed PMID: 25884116. Pubmed Central PMCID: 4496681.
38. Kim GH, Kim JE, Rhie SJ, Yoon S. The role of oxidative stress in neurodegenerative diseases. Exp Neurobiol. 2015;24(4):325-40. PubMed PMID: 26713080. Pubmed Central PMCID: 4688332.
39. Higdon A, Diers AR, OhJY, Landar A, Darley-UsmarVM. Cell signalling by reactive lipid species: New concepts and molecular mechanisms. Biochem J. 2012;442(3):453-64. PubMed PMID: 22364280. Pubmed Central PMCID: 3286857.
40. Hauck AK, BernlohrDA. Oxidative stress and lipotoxicity. J Lipid Res. 2016. PubMed PMID: 27009116.
41. Birben E, SahinerUM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5(1):9-19. PubMed PMID: 23268465. Pubmed Central PMCID: 3488923.
42. Rhee SG, Bae YS, Lee SR, Kwon J. Hydrogen peroxide: A key messenger that modulates protein phosphorylation through cysteine oxidation. Sci STKE. 2000;2000(53):pe1. PubMed PMID: 11752613.
43. Rhee SG. Cell signaling. H2O2, a necessary evil for cell signaling. Science. 2006;312(5782):1882-3. PubMed PMID: 16809515.
44. Finkel T. From sulfenylation to sulfhydration: What a thiolate needs to tolerate. Sci Signal. 2012;5(215):pe10. PubMed PMID: 22416275.
45. Janssen-Heininger YM, Mossman BT, Heintz NH, Forman HJ, Kalyanaraman B, Finkel T, et al. Redox-based regulation of signal transduction: Principles, pitfalls, and promises. Free Radic Biol Med. 2008;45(1):1-17. PubMed PMID: 18423411. Pubmed Central PMCID: 2453533.
46. Lee SR, Kwon KS, Kim SR, Rhee SG. Reversible inactivation of protein-tyrosine phosphatase 1B in A431 cells stimulated with epidermal growth factor. J Biol Chem. 1998;273(25):15366-72. PubMed PMID: 9624118.
47. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, et al. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A. 2004;101(47):16419-24. PubMed PMID: 15534200. Pubmed Central PMCID: 534546.
48. Matsushima S, Kuroda J, Ago T, Zhai P, Park JY, Xie LH, et al. Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy. Circ Res. 2013;112(4):651-63. PubMed PMID: 23271793. Pubmed Central PMCID: 3574183.
49. Weyemi U, Dupuy C. The emerging role of ROSgenerating NADPH oxidase NOX4 in DNA-damage responses. Mutat Res. 2012;751(2):77-81. PubMed PMID: 22580379.
50. Seth D, Rudolph J. Redox regulation ofMAPkinase phosphatase 3. Biochemistry. 2006;45(28):8476-87. PubMed PMID: 16834321.
51. Levinthal DJ, Defranco DB. Reversible oxidation of ERKdirected protein phosphatases drives oxidative toxicity in neurons. J Biol Chem. 2005;280(7):5875-83. PubMed PMID: 15579467.
52. Mannick JB, SchonhoffC, Papeta N, Ghafourifar P, Szibor M, Fang K, et al. S-Nitrosylation of mitochondrial caspases. J Cell Biol. 2001;154(6):1111-6. PubMed PMID: 11551979. Pubmed Central PMCID: 2150810.
53. Hoppe G, Chai YC, Crabb JW, Sears J. Protein s-glutathionylation in retinal pigment epithelium converts heat shock protein 70 to an active chaperone. Exp Eye Res. 2004;78(6):1085-92. PubMed PMID: 15109915.
54. Nardai G, Sass B, Eber J, Orosz G, Csermely P. Reactive cysteines of the 90-kDa heat shock protein, Hsp90. Arch Biochem Biophys. 2000;384(1):59-67. PubMed PMID: 11147836.
55. Tsai B, Rodighiero C, Lencer WI, Rapoport TA. Protein disulfide isomerase acts as a redox-dependent chaperone tounfold cholera toxin. Cell. 2001;104(6):937-48. PubMed PMID: 11290330.
56. West AP, Brodsky IE, Rahner C, Woo DK, Erdjument-Bromage H, Tempst P, et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature. 2011;472(7344):476-80. PubMed PMID: 21525932. Pubmed Central PMCID: 3460538.
57. Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, HildemanDA, et al. Mitochondria are required for antigenspecific T cell activation through reactive oxygen species signaling. Immunity. 2013;38(2):225-36. PubMed PMID: 23415911. Pubmed Central PMCID: 3582741.
58. Wheeler ML, Defranco AL. Prolonged production of reactive oxygen species in response to B cell receptor stimulation promotes B cell activation and proliferation. J Immunol. 2012;189(9):4405-16. PubMed PMID: 23024271. Pubmed Central PMCID: 3515638.
59. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci. 2009;29(43):13435-44. PubMed PMID: 19864556. Pubmed Central PMCID: 2788152.
60. Mills CD. M1 and M2 macrophages: Oracles of health and disease. Crit Rev Immunol. 2012;32(6):463-88. PubMed PMID: 23428224.
61. Haskew-Layton RE, Payappilly JB, Smirnova NA, Ma TC, Chan KK, Murphy TH, et al. Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. Proc Natl Acad Sci U S A. 2010;107(40):17385-90. PubMed PMID: 20855618. Pubmed Central PMCID: 2951414.
62. BrazierMW, Wedd AG, Collins SJ. Antioxidant and metal chelation-based therapies in the treatment of prion disease. Antioxidants (Basel). 2014;3(2):288-308. PubMed PMID: 26784872. Pubmed Central PMCID: 4665489.
63. Muller M, Leavitt BR. Iron dysregulation in Huntington's disease. J Neurochem. 2014;130(3):328-50. PubMed PMID: 24717009.
64. Bartzokis G, Lu PH, Geschwind DH, Tingus K, Huang D, Mendez MF, et al. Apolipoprotein E affects both myelin breakdown and cognition: Implications for age-related trajectories of decline into dementia. Biol Psychiatry. 2007;62(12):1380-7. PubMed PMID: 17659264.
65. Rosas HD, Chen YI, Doros G, Salat DH, Chen NK, Kwong KK, et al. Alterations in brain transition metals in Huntington disease: An evolving and intricate story. Arch Neurol. 2012;69(7):887-93. PubMed PMID: 22393169. Pubmed Central PMCID: 3652228.
66. Fox JH, Kama JA, Lieberman G, Chopra R, Dorsey K, ChopraV, et al. Mechanisms of copper ion mediated Huntington's disease progression. PLoS One. 2007;2(3):e334. PubMed PMID: 17396163. Pubmed Central PMCID: 1828629.
67. Chen J, Marks E, Lai B, Zhang Z, Duce JA, Lam LQ, et al. Iron accumulates in Huntington's disease neurons: Protection by deferoxamine. PLoS One. 2013;8(10):e77023. PubMed PMID: 24146952. Pubmed Central PMCID: 3795666.
68. Hands SL, Mason R, Sajjad MU, Giorgini F, Wyttenbach A. Metallothioneins and copper metabolism are candidate therapeutic targets in Huntington's disease. Biochem Soc Trans. 2010;38(2):552-8. PubMed PMID: 20298220.
69. Karuppagounder SS, Alim I, Khim SJ, Bourassa MW, Sleiman SF, John R, et al. Therapeutic targeting of oxygen-sensing prolyl hydroxylases abrogates ATF4-dependent neuronal death and improves outcomes after brain hemorrhage in several rodent models. Sci Transl Med. 2016;8(328):328ra29. PubMed PMID: 26936506.
70. Fox JH, Connor T, Stiles M, Kama J, Lu Z, DorseyK, et al. Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein. J Biol Chem. 2011;286(20):18320-30. PubMed PMID: 21454633. Pubmed Central PMCID: 3093904.
71. Xiao G, Fan Q, Wang X, Zhou B. Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding. Proc Natl Acad Sci U S A. 2013;110(37):14995-5000. PubMed PMID: 23980182. Pubmed Central PMCID: 3773747.
72. Mitomi Y, Nomura T, Kurosawa M, Nukina N, Furukawa Y. Post-aggregation oxidation of mutant huntingtin controls the interactions between aggregates. J Biol Chem. 2012;287(41):34764-75. PubMed PMID: 22891249. Pubmed Central PMCID: 3464579.
73. Barnham KJ, Bush AI. Biological metals and metaltargeting compounds in major neurodegenerative diseases. Chem Soc Rev. 2014;43(19):6727-49. PubMed PMID: 25099276.
74. Nguyen T, Hamby A, Massa SM. Clioquinol downregulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005;102(33):11840-5. PubMed PMID: 16087879. Pubmed Central PMCID: 1187967.
75. Cherny RA, Ayton S, Finkelstein DI, Bush AI, McColl G, Massa SM. PBT2 reduces toxicity in a C. elegans model of polyQ aggregation and extends lifespan, reduces striatal atrophy and improves motor performance in the R6/2 mouse model of Huntington's disease. J Huntingtons Dis. 2012;1(2):211-9. PubMed PMID: 25063332.
76. Huntington Study Group Reach HDI. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14(1):39-47. PubMed PMID: 25467848.
77. Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, et al. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem. 2005;280(50):41732-43. PubMed PMID: 16227210. Pubmed Central PMCID: 2586128.
78. Frijhoff J, Winyard PG, Zarkovic N, Davies SS, Stocker R, Cheng D, et al. Clinical relevance of biomarkers of oxidative stress. Antioxid Redox Signal. 2015;23(14):1144-70. PubMed PMID: 26415143. Pubmed Central PMCID: 4657513.
79. Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS, PREDICT-HDInvestigators and Coordinators of the Huntington Study Group. 8OHdG as a marker for Huntington disease progression. Neurobiol Dis. 2012;46(3):625-34. PubMed PMID: 22414782. Pubmed Central PMCID: 3784019.
80. Brocardo PS, McGinnis E, Christie BR, Gil-Mohapel J. Time-course analysis of protein and lipid oxidation in the brains of Yac128 Huntington's disease transgenic mice. Rejuvenation Res. 2016;19(2):140-8. PubMed PMID: 26371883.
81. Tunez I, Sanchez-Lopez F, Aguera E, Fernandez-Bolanos R, Sanchez FM, Tasset-Cuevas I. Important role of oxidative stress biomarkers in Huntington's disease. J Med Chem. 2011;54(15):5602-6. PubMed PMID: 21678912.
82. Thanan R, Oikawa S, Hiraku Y, Ohnishi S, Ma N, Pinlaor S, et al. Oxidative stress and its significant roles in neurodegenerative diseases and cancer. Int J Mol Sci. 2015;16(1):193-217. PubMed PMID: 25547488. Pubmed Central PMCID: 4307243.
83. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem. 2006;52(4):601-23. PubMed PMID: 16484333.
84. Murray CI, Van Eyk JE. Chasing cysteine oxidative modifications: Proteomic tools for characterizing cysteine redox status. Circ Cardiovasc Genet. 2012;5(5):591. PubMed PMID: 23074338. Pubmed Central PMCID: 3500588.
85. Stoy N, Mackay GM, Forrest CM, Christofides J, Egerton M, Stone TW, et al. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem. 2005;93(3):611-23. PubMed PMID: 15836620.
86. Browne SE, Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxid Redox Signal. 2006;8(11-12):2061-73. PubMed PMID: 17034350.
87. Andrade-Lima LC, Veloso A, Ljungman M. Transcription blockage leads to new beginnings. Biomolecules. 2015;5(3):1600-17. PubMed PMID: 26197343. Pubmed Central PMCID: 4598766.
88. Li J, O W, Li W, Jiang ZG, Ghanbari HA. Oxidative stress and neurodegenerative disorders. Int J Mol Sci. 2013;14(12):24438-75. PubMed PMID: 24351827. Pubmed Central PMCID: 3876121.
89. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia. Ann Neurol. 1997;41(5):646-53. PubMed PMID: 9153527.
90. Siddiqui A, Rivera-Sanchez S, Castro Mdel R, Acevedo-Torres K, Rane A, Torres-Ramos CA, et al. Mitochondrial DNA damage is associated with reduced mitochondrial bioenergetics in Huntington's disease. Free Radic Biol Med. 2012;53(7):1478-88. PubMed PMID: 22709585. Pubmed Central PMCID: 3846402.
91. Polyzos A, Holt A, Brown C, Cosme C, Wipf P, Gomez-Marin A, et al. Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes. Hum Mol Genet. 2016. PubMed PMID: 26908614.
92. Chen CM, Wu YR, Cheng ML, Liu JL, Lee YM, Lee PW, et al. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem Biophys Res Commun. 2007;359(2):335-40. PubMed PMID: 17543886.
93. Valencia A, Sapp E, Reeves PB, Alexander J, Masso N, Li X, et al. Reagents that block neuronal death from Huntington's disease also curb oxidative stress. Neuroreport. 2012;23(1):10-5. PubMed PMID: 22045254.
94. Polyzos A, Holt A, Brown C, Cosme C, Wipf P, Gomez-Marin A, et al. Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes. Hum Mol Genet. 2016;25(9):1792-802. PubMed PMID: 26908614.
95. Entezam A, Lokanga AR, Le W, Hoffman G, Usdin K. Potassium bromate, a potentDNAoxidizing agent, exacerbates germline repeat expansion in a fragileXpremutation mouse model. Hum Mutat. 2010;31(5):611-6. PubMed PMID: 20213777. Pubmed Central PMCID: 2951473.
96. Kovtun IV, Liu Y, Bjoras M, Klungland A, Wilson SH, McMurray CT. OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature. 2007;447(7143):447-52. PubMed PMID: 17450122. Pubmed Central PMCID: 2681094.
97. Jarem DA, Wilson NR, Delaney S. Structure-dependent DNA damage and repair in a trinucleotide repeat sequence. Biochemistry. 2009;48(28):6655-63. PubMed PMID: 19527055.
98. Pearson CE, Nichol Edamura K, Cleary JD. Repeat instability: Mechanisms of dynamic mutations. Nat Rev Genet. 2005;6(10):729-42. PubMed PMID: 16205713.
99. Mollersen L, Rowe AD, Illuzzi JL, Hildrestrand GA, Gerhold KJ, Tveteras L, et al. Neil1 is a genetic modifier of somatic and germline CAG trinucleotide repeat instability in R6/1 mice. Hum Mol Genet. 2012;21(22):4939-47. PubMed PMID: 22914735. Pubmed Central PMCID: 3607484.
100. Manley K, Shirley TL, Flaherty L, Messer A. Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nat Genet. 1999;23(4):471-3. PubMed PMID: 10581038.
101. Goula AV, Berquist BR, Wilson DM, Wheeler VC, Trottier Y, Merienne K. Stoichiometry of base excision repair proteins correlates with increased somaticCAGinstability in striatum over cerebellum in Huntington's disease transgenic mice. PLoS Genet. 2009;5(12):e1000749. PubMed PMID: 19997493. Pubmed Central PMCID: 2778875.
102. Cilli P, Ventura I, Minoprio A, Meccia E, Martire A, Wilson SH, et al. Oxidized dNTPs and the OGG1 and MUTYH DNA glycosylases combine to induce CAG/CTG repeat instability. Nucleic Acids Res. 2016. PubMed PMID: 26980281.
103. Budworth H, Harris FR, Williams P, Lee do Y, Holt A, Pahnke J, et al. Suppression of somatic expansion delays the onset of pathophysiology in a mouse model of Huntington's disease. PLoS Genet. 2015;11(8):e1005267. PubMed PMID: 26247199. Pubmed Central PMCID: 4527696.
104. Budworth H, McMurray CT. Problems and solutions for the analysis of somatic CAG repeat expansion and their relationship to Huntington's disease toxicity. Rare Dis. 2016;4(1):e1131885. PubMed PMID: 27141411. Pubmed Central PMCID: 4838321.
105. Enokido Y, Tamura T, Ito H, Arumughan A, Komuro A, Shiwaku H, et al. Mutant huntingtin impairs Ku70-mediated DNA repair. J Cell Biol. 2010;189(3):425-43. PubMed PMID: 20439996. Pubmed Central PMCID: 2867301.
106. Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo AP, Rubinsztein DC. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet. 2002;11(9):1137-51. PubMed PMID: 11978772.
107. Hands S, Sajjad MU, Newton MJ, Wyttenbach A. In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. J Biol Chem. 2011;286(52):44512-20. PubMed PMID: 21984825. Pubmed Central PMCID: 3247975.
108. Dragunow M, Faull RL, Lawlor P, Beilharz EJ, Singleton K, Walker EB, et al. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer'sdisease temporal lobes. Neuroreport. 1995;6(7):1053-7. PubMed PMID: 7632894.
109. Braak H, Braak E. Allocortical involvement in Huntington's disease. Neuropathol Appl Neurobiol. 1992;18(6):539-47. PubMed PMID: 1488086.
110. Sorolla MA, Rodriguez-Colman MJ, Tamarit J, Ortega Z, Lucas JJ, Ferrer I, et al. Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. Free Radic Biol Med. 2010;49(4):612-21. PubMed PMID: 20639122.
111. Brennan WA, Jr., Bird ED, Aprille JR. Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem. 1985;44(6):1948-50. PubMed PMID: 2985766.
112. Stahl WL, Swanson PD. Biochemical abnormalities in Huntington's chorea brains. Neurology. 1974;24(9):813-9. PubMed PMID: 4277376.
113. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol. 1996;39(3):385-9. PubMed PMID: 8602759.
114. Sorolla MA, Rodriguez-Colman MJ, Vall-llaura N, Tamarit J, Ros J, Cabiscol E. Protein oxidation in Huntington disease. Biofactors. 2012;38(3):173-85. PubMed PMID: 22473822.
115. Klepac N, Relja M, Klepac R, Hecimovic S, Babic T, Trkulja V. Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects : A crosssectional study. J Neurol. 2007;254(12):1676-83. PubMed PMID: 17990062.
116. Christofides J, Bridel M, Egerton M, Mackay GM, Forrest CM, Stoy N, et al. Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury. J Neurochem. 2006;97(4):1078-88. PubMed PMID: 16573644.
117. Chang KH, Chen YC, Wu YR, Lee WF, Chen CM. Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington's disease patients. PLoS One. 2012;7(9):e46492. PubMed PMID: 23029535. Pubmed Central PMCID: 3459918.
118. Pena-Sanchez M, Riveron-Forment G, Zaldivar-VaillantT, Soto-Lavastida A, Borrero-Sanchez J, Lara-Fernandez G, et al. Association of status redox with demographic, clinical and imaging parameters in patients with Huntington's disease. Clin Biochem. 2015;48(18):1258-63. PubMed PMID: 26210848.
119. Ciancarelli I, De Amicis D, Di Massimo C, Di Scanno C, Pistarini C, D'Orazio N, et al. Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington's patients. Biomarkers. 2014;19(6):452-6. PubMed PMID: 24980251.
120. Arenas J, Campos Y, Ribacoba R, Martin MA, Rubio JC, Ablanedo P, et al. Complex I defect in muscle from patients with Huntington's disease. Ann Neurol. 1998;43(3):397-400. PubMed PMID: 9506560.
121. Parker WD, Jr., Boyson SJ, Luder AS, Parks JK. Evidence for a defect in NADH: Ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology. 1990;40(8):1231-4. PubMed PMID: 2143271.
122. Powers WJ, Haas RH, Le T, Videen TO, Hershey T, McGee-Minnich L, et al. Normal platelet mitochondrial complex I activity in Huntington's disease. Neurobiol Dis. 2007;27(1):99-101. PubMed PMID: 17543533. Pubmed Central PMCID: 2140002.
123. Turner C, Cooper JM, Schapira AH. Clinical correlates of mitochondrial function in Huntington's disease muscle. Mov Disord. 2007;22(12):1715-21. PubMed PMID: 17557337.
124. Beal MF, Brouillet E, Jenkins B, Henshaw R, Rosen B, Hyman BT. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem. 1993;61(3):1147-50. PubMed PMID: 7689641.
125. Brouillet E, Jenkins BG, Hyman BT, Ferrante RJ, Kowall NW, Srivastava R, et al. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem. 1993;60(1):356-9. PubMed PMID: 8417157.
126. Brouillet E, Guyot MC, Mittoux V, Altairac S, Conde F, Palfi S, et al. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J Neurochem. 1998;70(2):794-805. PubMed PMID: 9453576.
127. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci. 1993;13(10):4181-92. PubMed PMID: 7692009.
128. Borlongan CV, Koutouzis TK, Randall TS, Freeman TB, Cahill DW, Sanberg PR. Systemic 3-nitropropionic acid: Behavioral deficits and striatal damage in adult rats. Brain Res Bull. 1995;36(6):549-56. PubMed PMID: 7538873.
129. Guyot MC, Hantraye P, Dolan R, Palfi S, Maziere M, Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience. 1997;79(1):45-56. PubMed PMID: 9178864.
130. Acevedo-Torres K, Berrios L, Rosario N, Dufault V, Skatchkov S, Eaton MJ, et al. MitochondrialDNAdamage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. DNARepair (Amst). 2009;8(1):126-36. PubMed PMID: 18935984. Pubmed Central PMCID: 3268004.
131. Lu XH, Mattis VB, Wang N, Al-Ramahi I, van den BergN, Fratantoni SA, et al. Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease. Sci Transl Med. 2014;6(268):268ra178. PubMed PMID: 25540325.
132. Shiloh Y, Ziv Y. The ATM protein kinase: Regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol. 2013;14(4):197-210. PubMed PMID: 23847781.
133. Ditch S, Paull TT. The ATM protein kinase and cellular redox signaling: Beyond the DNA damage response. Trends Biochem Sci. 2012;37(1):15-22. PubMed PMID: 22079189. Pubmed Central PMCID: 3259275.
134. Bogdanov MB, AndreassenOA, Dedeoglu A, Ferrante RJ, Beal MF. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. JNeurochem. 2001;79(6):1246-9. PubMed PMID: 11752065.
135. Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, et al. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci. 2008;28(24):6182-95. PubMed PMID: 18550760. Pubmed Central PMCID: 2630800.
136. Stack C, Ho D, Wille E, Calingasan NY, Williams C, Liby K, et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med. 2010;49(2):147-58. PubMed PMID: 20338236. Pubmed Central PMCID: 2916021.
137. Hong C, Seo H, Kwak M, Jeon J, Jang J, Jeong EM, et al. Increased TRPC5 glutathionylation contributes to striatal neuron loss in Huntington's disease. Brain. 2015;138(Pt 10):3030-47. PubMed PMID: 26133660. Pubmed Central PMCID: 4643628.
138. Illuzzi J, Yerkes S, Parekh-Olmedo H, Kmiec EB. DNA breakage and induction of DNA damage response proteins precede the appearance of visible mutant huntingtin aggregates. J Neurosci Res. 2009;87(3):733-47. PubMed PMID: 18831068.
139. Tsien RY, Pozzan T, Rink TJ. Calcium homeostasis in intact lymphocytes: Cytoplasmic free calcium monitored with a new, intracellularly trapped fluorescent indicator. J Cell Biol. 1982;94(2):325-34. PubMed PMID: 6980885. Pubmed Central PMCID: 2112871.
140. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260(6):3440-50. PubMed PMID: 3838314.
141. Winterbourn CC. The challenges of using fluorescent probes to detect and quantify specific reactive oxygen species in living cells. Biochim Biophys Acta. 2014;1840(2):730-8. PubMed PMID: 23665586.
142. Kalyanaraman B, Darley-Usmar V, Davies KJ, Dennery PA, Forman HJ, Grisham MB, et al. Measuring reactive oxygen and nitrogen species with fluorescent probes: Challenges and limitations. Free Radic Biol Med. 2012;52(1):1-6. PubMed PMID: 22027063. Pubmed Central PMCID: 3911769.
143. Belousov VV, Fradkov AF, Lukyanov KA, Staroverov DB, Shakhbazov KS, Terskikh AV, et al. Genetically encoded fluorescent indicator for intracellular hydrogen peroxide. Nat Methods. 2006;3(4):281-6. PubMed PMID: 16554833.
144. Perez-Severiano F, Rios C, Segovia J. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res. 2000;862(1-2):234-7. PubMed PMID: 10799690.
145. Perez-Severiano F, Escalante B, Vergara P, Rios C, Segovia J. Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation. Brain Res. 2002;951(1):36-42. PubMed PMID: 12231454.
146. Brocardo PS, McGinnis E, Christie BR, Gil-Mohapel J. Time-course analysis of protein and lipid oxidation in the brains of Yac128 Huntington's disease transgenic mice. Rejuvenation Res. 2016. PubMed PMID: 26371883.
147. Khoshnan A, Patterson PH. The role of IkappaB kinase complex in the neurobiology of Huntington's disease. Neurobiol Dis. 2011;43(2):305-11. PubMed PMID: 21554955. Pubmed Central PMCID: 3124142.
148. Bae BI, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y, et al. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron. 2005;47(1):29-41. PubMed PMID: 15996546.
149. Shimohata T, Nakajima T, Yamada M, Uchida C, Onodera O, Naruse S, et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet. 2000;26(1):29-36. PubMed PMID: 10973244.
150. Ng CW, Yildirim F, Yap YS, Dalin S, Matthews BJ, Velez PJ, et al. Extensive changes in DNA methylation are associated with expression of mutant huntingtin. Proc Natl Acad Sci U S A. 2013;110(6):2354-9. PubMed PMID: 23341638. Pubmed Central PMCID: 3568325.
151. Demple B, Harrison L. Repair of oxidative damage to DNA: Enzymology and biology. Annu Rev Biochem. 1994;63:915-48. PubMed PMID: 7979257.
152. Luo M, He H, Kelley MR, Georgiadis MM. Redox regulation of DNA repair: Implications for human health and cancer therapeutic development. Antioxid Redox Signal. 2010;12(11):1247-69. PubMed PMID: 19764832. Pubmed Central PMCID: 2864659.
153. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med. 2004;10(11):549-57. PubMed PMID: 15519281.
154. Itoh K, Wakabayashi N, KatohY, Ishii T, Igarashi K, Engel JD, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13(1):76-86. PubMed PMID: 9887101. Pubmed Central PMCID: 316370.
155. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A. 2002;99(18):11908-13. PubMed PMID: 12193649. Pubmed Central PMCID: 129367.
156. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004;24(16):7130-9. PubMed PMID: 15282312. Pubmed Central PMCID: 479737.
157. Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: Oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol. 2004;24(19):8477-86. PubMed PMID: 15367669. Pubmed Central PMCID: 516753.
158. Smirnova NA, Haskew-Layton RE, Basso M, Hushpulian DM, Payappilly JB, Speer RE, et al. Development of Neh2-luciferase reporter and its application for high throughput screening and real-time monitoring of Nrf2 activators. Chem Biol. 2011;18(6):752-65. PubMed PMID: 21700211. Pubmed Central PMCID: 3251032.
159. Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic Biol Med. 2009;47(9):1304-9. PubMed PMID: 19666107. Pubmed Central PMCID: 2763938.
160. Calkins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW, Johnson JA. Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci U S A. 2005;102(1):244-9. PubMed PMID: 15611470. Pubmed Central PMCID: 538748.
161. Shih AY, Imbeault S, Barakauskas V, Erb H, Jiang L, Li P, et al. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrialstress in vivo. J Biol Chem. 2005;280(24):22925-36. PubMed PMID: 15840590.
162. Calkins MJ, Townsend JA, Johnson DA, Johnson JA. Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription. Exp Neurol. 2010;224(1):307-17. PubMed PMID: 20406637. Pubmed Central PMCID: 2885467.
163. Calkins MJ, Vargas MR, Johnson DA, Johnson JA. Astrocyte-specific overexpression of Nrf2 protects striatal neurons from mitochondrial complex II inhibition. Toxicol Sci. 2010;115(2):557-68. PubMed PMID: 20211941. Pubmed Central PMCID: 2871759.
164. Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, Saft C, et al. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One. 2011;6(1):e16172. PubMed PMID: 21297955. Pubmed Central PMCID: 3031519.
165. Brennan MS, Patel H, Allaire N, Thai A, Cullen P, Ryan S, et al. Pharmacodynamics of dimethyl fumarate are tissue specific and involve NRF2-dependent and-independent mechanisms. Antioxid Redox Signal. 2016;24(18):1058-71. PubMed PMID: 26980071.
166. D'Autreaux B, Toledano MB. ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol. 2007;8(10):813-24. PubMed PMID: 17848967.
167. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005;434(7029):113-8. PubMed PMID: 15744310.
168. Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1alpha. J Biol Chem. 2005;280(16):16456-60. PubMed PMID: 15716268.
169. Garriga-Canut M, Schoenike B, Qazi R, Bergendahl K, Daley TJ, Pfender RM, et al. 2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat Neurosci. 2006;9(11):1382-7. PubMed PMID: 17041593.
170. Fulco M, Schiltz RL, Iezzi S, King MT, Zhao P, KashiwayaY, et al. Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol Cell. 2003;12(1):51-62. PubMed PMID: 12887892.
171. Zhang Q, Piston DW, Goodman RH. Regulation of corepressor function by nuclear NADH. Science. 2002;295(5561):1895-7. PubMed PMID: 11847309.
172. Ryu H, Lee J, Olofsson BA, Mwidau A, Dedeoglu A, Escudero M, et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci U S A. 2003;100(7):4281-6. PubMed PMID: 12640146. Pubmed Central PMCID: 153084.
173. Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD, et al. Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci. 2003;23(9):3597-606. PubMed PMID: 12736330.
174. Paul BD, Sbodio JI, Xu R, Vandiver MS, Cha JY, Snowman AM, et al. Cystathionine gamma-lyase deficiency mediates neurodegeneration in Huntington's disease. Nature. 2014;509(7498):96-100. PubMed PMID: 24670645. Pubmed Central PMCID: 4349202.
175. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science. 2002;296(5576):2238-43. PubMed PMID: 11988536.
176. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005;1(6):361-70. PubMed PMID: 16054085.
177. Starkov AA. The role of mitochondria in reactive oxygen species metabolism and signaling. Ann N Y Acad Sci. 2008;1147:37-52. PubMed PMID: 19076429. Pubmed Central PMCID: 2869479.
178. Starkov AA, Andreyev AY, Zhang SF, Starkova NN, Korneeva M, Syromyatnikov M, et al. Scavenging of H2O2 by mouse brain mitochondria. J Bioenerg Biomembr. 2014;46(6):471-7. PubMed PMID: 25248416. Pubmed Central PMCID: 4634880.
179. Song B, Scheuner D, Ron D, Pennathur S, Kaufman RJ. Chop deletion reduces oxidative stress, improves beta cell function, and promotes cell survival in multiple mouse models of diabetes. J Clin Invest. 2008;118(10):3378-89. PubMed PMID: 18776938. Pubmed Central PMCID: 2528909.
180. Freeman TC, Wood IS, Sirinathsinghji DJ, Beechey RB, Dyer J, Shirazi-Beechey SP. The expression of the Na+/glucose cotransporter (SGLT1) gene in lamb small intestine during postnatal development. Biochim Biophys Acta. 1993;1146(2):203-12. PubMed PMID: 8452856.
181. Tell G, Zecca A, Pellizzari L, Spessotto P, Colombatti A, Kelley MR, et al. An environment to nucleus signaling system operates in B lymphocytes: Redox status modulates BSAP/Pax-5 activation through Ref-1 nuclear translocation. Nucleic Acids Res. 2000;28(5):1099-105. PubMed PMID: 10666449. Pubmed Central PMCID: 102597.